May 14, 2022
Article
“Relugolix, an oral nonpeptide GnRH receptor antagonist, was generally well tolerated in the phase 3 HERO study,” wrote Bryan Mehlhaff, MD, and coauthors.
February 19, 2022
Article
BAYOU trial results showed no significant PFS boost in all-comer population with addition of olaparib to frontline durvalumab in metastatic urothelial carcinoma, but potential benefit for combo was observed in HRR-mutation–positive subgroup.
September 13, 2021
Article
The mitomycin-containing reverse thermal gel UGN-101 (Jelmyto) produced durable responses in patients with low-grade upper tract urothelial carcinoma.
September 11, 2021
Article
The prognostic factor analysis included patients who received either 177Lu-PSMA-617 or 177Lu-J591.